ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO642

Characteristics of Patients with Complement 3 Glomerulopathy (C3G) in a US Multi-Center Assessment

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Ndife, Briana C., Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
  • Aldworth, Carolina A R, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
  • Murphy, Kathleen, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
  • Nguyen, Jennifer, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
  • Pivneva, Irina, Analysis Group Inc Boston, Boston, Massachusetts, United States
  • Edwards, Marie Louise, Analysis Group Inc Boston, Boston, Massachusetts, United States
  • Anderson, Annika, Analysis Group Inc Boston, Boston, Massachusetts, United States
  • Signorovitch, James, Analysis Group Inc Boston, Boston, Massachusetts, United States
  • Canetta, Pietro A., Columbia University Irving Medical Center, New York, New York, United States
Background

C3G is characterized by C3 deposition in the glomeruli caused by abnormal activation of the alternative complement pathway. There are no approved therapies for C3G. Despite supportive care, C3G remains a progressive form of kidney disease, with novel treatments needed to improve outcomes.

Contemporary datasets on the clinical burden of patients with C3G are limited. Using real-world evidence from electronic medical records, this study describes the characteristics of patients diagnosed with C3G in the US.

Methods

This was a retrospective cohort study of patients included in the US Optum Life Science clinical electronic health record database who were aged ≥12 years at C3G diagnosis (per ICD-10 or SNOMED; index date) between 01/2015 and 06/2022. Patients had continuous clinical activity ≥12 months before (baseline) and ≥6 months after (follow-up) index date, and were followed until death or data end. Patient and clinical characteristics at index date were evaluated using descriptive statistics.

Results

Of 284 patients in the final sample, 78% were White, 11% African American, 2% Asian, and 10% other/unknown. Mean age ± SD was 49 ± 21 years, 50% were male, and 136/228 (60%) had stage ≥3 CKD at index.

At baseline, mean Charlson Comorbidity Index (CCI) score ± SD was 2.3 ± 2.7. Of comorbidities included in the CCI, the most common included chronic pulmonary disease (25%) and diabetes without chronic complication (20%). At baseline, hypertension (65%) was the most common C3G-related comorbidity; 10% of patients had undergone dialysis and 12% kidney transplant. Obesity (BMI ≥30) was recorded in 100/249 patients (40%). Common C3G-related treatments at baseline included corticosteroids (54%), ACE inhibitors (41%), ARBs (26%) and immunosuppressants (21%). At baseline, proteinuria was assessed in 126 patients (44%); mean protein/creatinine ratio ± SD was 2.9 ± 3.9 g/g. Of 100 patients (35%) with available data, 34% had complement C3 level <77 mg/dl.

Conclusion

This contemporary assessment of patients with C3G from a national US cohort identified a population that presented with multiple comorbidities and advanced kidney disease around the time of diagnosis.

Funding

  • Commercial Support – Novartis Pharmaceuticals Corporation